Trial Profile

Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
Indications B-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms PrE0403

Most Recent Events

28 Feb 2023 Status changed from active, no longer recruiting to completed.
22 Dec 2021 Planned End Date changed from 1 Jan 2024 to 1 Jun 2023.
14 Dec 2021 Results assessing end of induction (EOI) outcomes presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com